搜尋結果

共 1996 個結果
頁數:1...29 30 31 32 33 34 35 36 37 ...100

Self-reliance will cut China growth, drive out foreign firms

... ly during Covid-19. “China made an impressive recovery from the COVID-19 pandemic, In 2020, many European Chamber members posted record revenue and profits, helping to stabilise their headquarters and ...More

EJ Insight2021-09-24

Taming the stagflationary winds

... he latest COVID-19 wave. And they take comfort from multiplying signs of booming corporate investment in response to supply disruptions. Others are more pessimistic. They argue that demand headwinds w ...More

EJ Insight2021-09-24

Consensus in Japan's ruling LDP turns against China

... ng of the Covid-19 epidemic. Anti-Japanese propaganda i ...全文

今日信報時事評論EJ InsightMark O’Neill2021年09月24日

Consensus in Japan’s ruling LDP turns against China

... ng of the Covid-19 epidemic. Anti-Japanese propaganda in the mainland is unrelenting, with war films, documentaries and giant memorial events held. Earlier this month, the government closed Tang Littl ...More

EJ Insight2021-09-23

New business models for a new future

COVID-19 has sharpened the focus on many challenges with which the world has long been grappling, including rising inequality, insufficient access to adequate health care and education, and climate ch ...More

EJ Insight2021-09-21

專員的力量

... 架構的從屬和運作。 COVID-19肆虐全球已近兩年,變種病毒不斷出現,人類的疫苗注射從攻勢轉為守勢,歐美國家 ...全文

今日信報副刊文化身心掃描陳仲謀醫生2021年09月21日

疫後充分運用設備即服務(DaaS) 掌握靈活設備的優勢 迎接變幻莫測的未來

... 即服務發展(Why COVID-19 Drove an Increase in DaaS)[2] 資料來源:I ...全文

2021年09月20日

Passing into nothingness

... spread of Covid-19, what I am unable to reconcile with this objective is the necessity to imprison those who have received double vaccination against Covid-19, and have had positive anti-body tests. C ...More

EJ Insight2021-09-20

Towards a more reasonable, effective quarantine policy

... ations of COVID-19 that behoove and call for us to exer ...全文

今日信報時事評論EJ InsightBrian Wong2021年09月18日

君實生物(01877) 其他-業務發展最新情況

... 急使用授權範圍擴大至COVID-19的暴露後預防(189KB, pdf) ...全文

即時新聞港交所通告2021年09月17日

君實生物(01877) 海外監管公告-業務發展最新情況

... 用授權用於暴露後預防COVID-19的公告(309KB, pdf) ...全文

即時新聞港交所通告2021年09月17日

Investors should focus on China’s diversification value

... ipts. The Covid-19 pandemic has driven China’s economic and policy cycles to become de-synchronised from the rest of the world. China was the only major economy to enjoy positive growth in 2020 and th ...More

EJ Insight2021-09-17

Towards a more reasonable, effective quarantine policy

... ations of COVID-19 that behoove and call for us to exercise both due diligence and caution in our approach to public health policies. Yet this is, in equal parts, by no means an excuse for a quarantin ...More

EJ Insight2021-09-17

Will the BRICS ever grow up?

... s. And as COVID-19 has shown, most have health systems that are poorly equipped to deal with pandemics. Unless they treat global infectious diseases more seriously, they will never be able to reach th ...More

EJ Insight2021-09-17

越南製造加工出口(00422) 其他-業務發展最新情況

越南製造加工出口(00422) 自願性公告越南仁澤生產設施在 COVID-19 於越南最近發展下的進一步最新營 ...全文

即時新聞港交所通告2021年09月16日

The economic risks of Pandexit

... o put the COVID-19 pandemic behind us, and go back to kissing casual acquaintances (on the cheek at least) and jamming ourselves like sardines into trams and trains in cities from New York to Tokyo. T ...More

EJ Insight2021-09-16

This SDR allocation must be different

...  meet the COVID-19 emergency. SDRs are bookkeeping claims that governments, through the IMF’s good offices, can convert into dollars and other hard currencies to pay for essential imports, such as vac ...More

EJ Insight2021-09-15

港股兩日插703點 恒大債拖冧內房物管

... ovidence訂立COVID-19疫苗授權許可協議,合作製造、開發及商業化mRNA新冠疫苗,股價升5.9%。 ...全文

即時新聞港股直擊2021年09月14日

【異動股】雲頂新耀飆一成 奪mRNA新冠疫苗授權

... ovidence訂立COVID-19疫苗授權許可協議,雙方合作製造、開發及商業化COVID-19疫苗,當中包括 ...全文

即時新聞港股直擊2021年09月14日

雲頂新耀-B(01952) 須予披露的交易 / 代價發行

雲頂新耀-B(01952) 須予披露交易 - 有關COVID-19 疫苗及若干授權產品的製造、開發及商業化的( ...全文

即時新聞港交所通告2021年09月13日

頁數:1...29 30 31 32 33 34 35 36 37 ...100

信報簡介 | 服務條款 | 私隱條款 | 免責聲明 | 廣告查詢 | 加入信報 | 聯絡信報

股票及指數資料由財經智珠網有限公司提供。期貨指數資料由天滙財經有限公司提供。外滙及黃金報價由路透社提供。

本網站的內容概不構成任何投資意見,本網站內容亦並非就任何個別投資者的特定投資目標、財務狀況及個別需要而編製。投資者不應只按本網站內容進行投資。在作出任何投資決定前,投資者應考慮產品的特點、其本身的投資目標、可承受的風險程度及其他因素,並適當地尋求獨立的財務及專業意見。本網站及其資訊供應商竭力提供準確而可靠的資料,但並不保證資料絕對無誤,資料如有錯漏而令閣下蒙受損失,本公司概不負責。